Cargando…

Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung

BACKGROUND: There are few reports about the factor influencing the prognosis of high-grade neuroendocrine carcinoma. In this study, we evaluated surgical outcome of clinical stage I high-grade neuroendocrine carcinoma. METHODS: Patients who underwent curative surgery for high-grade neuroendocrine tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mochizuki, Eisuke, Matsuura, Shun, Oishi, Kyohei, Miyashita, Koichi, Ichijyo, Koshiro, Furukawa, Syunya, Nagaoka, Miyuki, Mikura, Shinichiro, Tsukui, Masaru, Koshimizu, Naoki, Sakurai, Shogo, Asada, Kazuhiro, Shirai, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816519/
https://www.ncbi.nlm.nih.gov/pubmed/29454358
http://dx.doi.org/10.1186/s12957-018-1337-2
_version_ 1783300693462876160
author Mochizuki, Eisuke
Matsuura, Shun
Oishi, Kyohei
Miyashita, Koichi
Ichijyo, Koshiro
Furukawa, Syunya
Nagaoka, Miyuki
Mikura, Shinichiro
Tsukui, Masaru
Koshimizu, Naoki
Sakurai, Shogo
Asada, Kazuhiro
Shirai, Toshihiro
author_facet Mochizuki, Eisuke
Matsuura, Shun
Oishi, Kyohei
Miyashita, Koichi
Ichijyo, Koshiro
Furukawa, Syunya
Nagaoka, Miyuki
Mikura, Shinichiro
Tsukui, Masaru
Koshimizu, Naoki
Sakurai, Shogo
Asada, Kazuhiro
Shirai, Toshihiro
author_sort Mochizuki, Eisuke
collection PubMed
description BACKGROUND: There are few reports about the factor influencing the prognosis of high-grade neuroendocrine carcinoma. In this study, we evaluated surgical outcome of clinical stage I high-grade neuroendocrine carcinoma. METHODS: Patients who underwent curative surgery for high-grade neuroendocrine tumors of the lung in clinical stage I were included in this study. We retrospectively analyzed 27 consecutive patients. The aim of this study was to clarify the clinical course of the disease after surgery and what factors influence the prognosis. RESULTS: Twenty-two patients have small cell carcinoma, and 5 patients have large cell neuroendocrine carcinoma. Patients who could undergo surgery within 60 days after the first visit (p < 0.01) and undergo lobectomy (p < 0.01) and whose pro-gastrin-releasing peptide ≦ 72 pg/ml (p = 0.04) performed good prognosis after surgery. In multivariate analysis, surgery within 60 days and operative procedure were independent factors associated with OS. CONCLUSION: Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung should be performed as early as possible, and better outcome can be obtained with lobectomy than partial resection.
format Online
Article
Text
id pubmed-5816519
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58165192018-02-21 Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung Mochizuki, Eisuke Matsuura, Shun Oishi, Kyohei Miyashita, Koichi Ichijyo, Koshiro Furukawa, Syunya Nagaoka, Miyuki Mikura, Shinichiro Tsukui, Masaru Koshimizu, Naoki Sakurai, Shogo Asada, Kazuhiro Shirai, Toshihiro World J Surg Oncol Research BACKGROUND: There are few reports about the factor influencing the prognosis of high-grade neuroendocrine carcinoma. In this study, we evaluated surgical outcome of clinical stage I high-grade neuroendocrine carcinoma. METHODS: Patients who underwent curative surgery for high-grade neuroendocrine tumors of the lung in clinical stage I were included in this study. We retrospectively analyzed 27 consecutive patients. The aim of this study was to clarify the clinical course of the disease after surgery and what factors influence the prognosis. RESULTS: Twenty-two patients have small cell carcinoma, and 5 patients have large cell neuroendocrine carcinoma. Patients who could undergo surgery within 60 days after the first visit (p < 0.01) and undergo lobectomy (p < 0.01) and whose pro-gastrin-releasing peptide ≦ 72 pg/ml (p = 0.04) performed good prognosis after surgery. In multivariate analysis, surgery within 60 days and operative procedure were independent factors associated with OS. CONCLUSION: Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung should be performed as early as possible, and better outcome can be obtained with lobectomy than partial resection. BioMed Central 2018-02-17 /pmc/articles/PMC5816519/ /pubmed/29454358 http://dx.doi.org/10.1186/s12957-018-1337-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mochizuki, Eisuke
Matsuura, Shun
Oishi, Kyohei
Miyashita, Koichi
Ichijyo, Koshiro
Furukawa, Syunya
Nagaoka, Miyuki
Mikura, Shinichiro
Tsukui, Masaru
Koshimizu, Naoki
Sakurai, Shogo
Asada, Kazuhiro
Shirai, Toshihiro
Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung
title Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung
title_full Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung
title_fullStr Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung
title_full_unstemmed Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung
title_short Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung
title_sort surgical resection for clinical stage i high-grade neuroendocrine carcinoma of the lung
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816519/
https://www.ncbi.nlm.nih.gov/pubmed/29454358
http://dx.doi.org/10.1186/s12957-018-1337-2
work_keys_str_mv AT mochizukieisuke surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT matsuurashun surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT oishikyohei surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT miyashitakoichi surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT ichijyokoshiro surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT furukawasyunya surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT nagaokamiyuki surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT mikurashinichiro surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT tsukuimasaru surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT koshimizunaoki surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT sakuraishogo surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT asadakazuhiro surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung
AT shiraitoshihiro surgicalresectionforclinicalstageihighgradeneuroendocrinecarcinomaofthelung